Sally F Barrington

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3600641/sally-f-barrington-publications-by-year.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

117 papers	10,526 citations	39 h-index	102 g-index
131 ext. papers	13,170 ext. citations	6.8 avg, IF	5.92 L-index

#	Paper	IF	Citations
117	Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.. *Journal of Clinical Oncology*, **2022**, JCO2102063	2.2	3
116	PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study. *Blood*, **2021**, 138, 2750-2750	2.2	
115	Not Yet Time to Abandon the Deauville Criteria in Diffuse Large B-Cell Lymphoma. *Journal of Nuclear Medicine*, **2021**, 62, 1655-1656	8.9	3
114	Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. *Blood Advances*, **2021**, 5, 2375-2384	7.8	9
113	A Retrospective Case Series Analysis of the Relationship Between Phenylalanine: Tyrosine Ratio and Cerebral Glucose Metabolism in Classical Phenylketonuria and Hyperphenylalaninemia. *Frontiers in Neuroscience*, **2021**, 15, 664525	5.1	1
112	FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study. *British Journal of Haematology*, **2021**, 192, 504-513	4.5	11
111	Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium. *Journal of Nuclear Medicine*, **2021**, 62, 332-337	8.9	10
110	Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). *British Journal of Haematology*, **2021**, 193, 63-71	4.5	5
109	COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial. *British Journal of Haematology*, **2021**, 192, e14-e16	4.5	5
108	The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma. *Lancet Haematology,the*, **2021**, 8, e80-e93	14.6	16
107	The role of PET in first-line treatment of Hodgkin lymphoma. *Lancet Haematology,the*, **2021**, 8, e67-e79	14.6	9
106	An overview of nuclear medicine research in the UK and the landscape for clinical adoption. *Nuclear Medicine Communications*, **2021**, 42, 1301-1312	1.6	
105	Robustness and Generalizability of Deep Learning Synthetic Computed Tomography for Positron Emission Tomography/Magnetic Resonance Imaging-Based Radiation Therapy Planning of Patients With Head and Neck Cancer. *Advances in Radiation Oncology*, **2021**, 6, 100762	3.3	2
104	Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial. *PLoS ONE*, **2020**, 15, e0231027	3.7	5
103	Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma. *Molecular Imaging and Biology*, **2020**, 22, 1102-1110	3.8	11
102	Enhanced Outcome Prediction in Early Stage Classical Hodgkin Lymphoma Using Pre-Treatment Biomarkers and Interim PET (BioPET); A Sub-Analysis of the UK NCRI RAPID Trial. *Blood*, **2020**, 136, 18-19	2.2	
101	The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World. *Blood*, **2020**, 136, 30-31	2.2	2

100	Reply to LTE: Automated segmentation of TMTV in DLBCL patients: what about method measurement uncertainty?. *Journal of Nuclear Medicine*, **2020**,	8.9	2
99	Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study. *Blood*, **2020**, 135, 1214-1218	2.2	18
98	Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. *Blood Advances*, **2020**, 4, 203-206	7.8	10
97	Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. *Haematologica*, **2020**, 105, 318-321	6.6	2
96	Guidance on the use of PET for treatment planning in radiotherapy clinical trials. *British Journal of Radiology*, **2019**, 92, 20190180	3.4	4
95	Reply to H.J.A. Adams et al and C. Kobe et al. *Journal of Clinical Oncology*, **2019**, 37, 3325-3326	2.2	
94	Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? - Authors' reply. *Lancet Oncology, The*, **2019**, 20, e5	21.7	1
93	Machine-learned target volume delineation of F-FDG PET images after one cycle of induction chemotherapy. *Physica Medica*, **2019**, 61, 85-93	2.7	5
92	Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. *Journal of Clinical Oncology*, **2019**, 37, 1732-1741	2.2	26
91	Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy. *British Journal of Haematology*, **2019**, 186, 431-439	4.5	6
90	Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden. *Journal of Nuclear Medicine*, **2019**, 60, 1096-1102	8.9	54
89	A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. *Hematological Oncology*, **2019**, 37, 352-359	1.3	12
88	Scan preparation for patients with type I diabetes treated with continuous sub-cutaneous insulin infusion (CSII) pumps. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 2217	8.8	
87	The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium. *Blood*, **2019**, 134, 487-487	2.2	4
86	Updating PET/CT performance standards and PET/CT interpretation criteria should go hand in hand. *EJNMMI Research*, **2019**, 9, 95	3.6	2
85	Simultaneous N-Ammonia and gadolinium first-pass myocardial perfusion with quantitative hybrid PET-MR imaging: a phantom and clinical feasibility study. *European Journal of Hybrid Imaging*, **2019**, 3, 15	1.7	6
84	The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper. *British Journal of Haematology*, **2019**, 185, 402-409	4.5	7
83	Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 520-521	8.8	8

82	Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 1142-1154	8.8	67
81	Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?. *Journal of Nuclear Medicine*, **2018**, 59, 1167-1169	8.9	19
80	PET/MRI in Lymphoma **2018**, 373-400		1
79	Reply to the letter. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 1834-1835	8.8	1
78	Three Cases of Hereditary Tyrosinaemia Type 1: Neuropsychiatric Outcomes and Brain Imaging Following Treatment with NTBC. *JIMD Reports*, **2018**, 40, 97-103	1.9	5
77	Role of PET imaging in adaptive radiotherapy for lymphoma. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 62, 411-419	1.4	2
76	All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 316-317	8.8	16
75	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 1530-1542	21.7	59
74	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. *European Journal of Cancer*, **2017**, 75, 195-203	7.5	35
73	Report of the 6th International Workshop on PET in lymphoma. *Leukemia and Lymphoma*, **2017**, 58, 2298-2303	4.9	15
72	FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 97-110	8.8	136
71	Association between hypoxic volume and underlying hypoxia-induced gene expression in oropharyngeal squamous cell carcinoma. *British Journal of Cancer*, **2017**, 116, 1057-1064	8.7	19
70	New horizons in multimodality molecular imaging and novel radiotracers. *Clinical Medicine*, **2017**, 17, 444-448	1.9	2
69	CXCR2 Inhibition - a novel approach to treating CoronAry heart DiseAse (CICADA): study protocol for a randomised controlled trial. *Trials*, **2017**, 18, 473	2.8	9
68	Guidelines for the use of imaging in the management of patients with myeloma. *British Journal of Haematology*, **2017**, 178, 380-393	4.5	77
67	F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?. *Journal of Nuclear Medicine*, **2017**, 58, 1539-1544	8.9	21
66	Reply to: Laffon and Marthan "FDG PET for therapy monitoring in Hodgkin's and non-Hodgkin's lymphomas: qPET versus rPET". *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 2331-2332	8.8	1
65	Effect of Bayesian-penalized likelihood reconstruction on [13N]-NH3 rest perfusion quantification. *Journal of Nuclear Cardiology*, **2017**, 24, 282-290	2.1	7

64	Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study. *Hematological Oncology*, **2017**, 35, 548-553	1.3	15
63	Imaging biomarker roadmap for cancer studies. *Nature Reviews Clinical Oncology*, **2017**, 14, 169-186	19.4	532
62	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. *Blood*, **2016**, 128, 2489-2496	2.2	235
61	A rare intravascular tumour diagnosed by endobronchial ultrasound. *Thorax*, **2016**, 71, 869-70	7.3	
60	Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. *New England Journal of Medicine*, **2016**, 374, 2419-29	59.2	428
59	(18)F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1239-47	8.8	28
58	Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1209-19	8.8	147
57	PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas. *Current Hematologic Malignancy Reports*, **2016**, 11, 185-95	4.4	15
56	PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. *Blood*, **2016**, 127, 1531-8	2.2	105
55	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. *British Journal of Haematology*, **2016**, 175, 876-883	4.5	18
54	Guidelines for the management of diffuse large B-cell lymphoma. *British Journal of Haematology*, **2016**, 174, 43-56	4.5	84
53	FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. *European Journal of Nuclear Medicine and Molecular Imaging*, **2015**, 42, 328-54	8.8	1446
52	Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. *New England Journal of Medicine*, **2015**, 372, 1598-607	59.2	437
51	PET-Directed Therapy for Hodgkin's Lymphoma. *New England Journal of Medicine*, **2015**, 373, 392	59.2	15
50	FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma. *Clinical and Translational Imaging*, **2015**, 3, 271-281	2	1
49	Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. *Journal of Clinical Oncology*, **2015**, 33, 1221-3	2.2	3
48	Reply to G. Keramida et al. *Journal of Clinical Oncology*, **2015**, 33, 4121-2	2.2	1
47	Analysis of loco-regional failures in head and neck cancer after radical radiation therapy. *Oral Oncology*, **2015**, 51, 1051-1055	4.4	35

46	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. *Blood*, **2015**, 126, 3905-3905	2.2	1
45	Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *Journal of Clinical Oncology*, **2014**, 32, 3059-68	2.2	2407
44	Guidelines for the first line management of classical Hodgkin lymphoma. *British Journal of Haematology*, **2014**, 166, 34-49	4.5	52
43	Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. *Journal of Clinical Oncology*, **2014**, 32, 3048-58	2.2	927
42	Applications of positron emission tomography in neuro-oncology: a clinical approach. *Journal of the Royal College of Surgeons of Edinburgh*, **2014**, 12, 148-57	2.5	18
41	When should FDG-PET be used in the modern management of lymphoma?. *British Journal of Haematology*, **2014**, 164, 315-28	4.5	44
40	Interictal estimation of intracranial seizure onset in temporal lobe epilepsy. *Clinical Neurophysiology*, **2014**, 125, 231-8	4.3	13
39	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. *Haematologica*, **2014**, 99, 1107-13	6.6	179
38	The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2014**, 41, 276-82	8.8	49
37	International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. *Journal of Nuclear Medicine*, **2013**, 54, 683-90	8.9	224
36	Comparing approaches to correct for respiratory motion in NH3 PET-CT cardiac perfusion imaging. *Nuclear Medicine Communications*, **2013**, 34, 1174-84	1.6	7
35	PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. *Blood*, **2013**, 122, 61-7	2.2	163
34	Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. *Journal of Thoracic Oncology*, **2013**, 8, 783-7	8.9	64
33	Is it all cerebral toxoplasmosis?. *Lancet, The*, **2012**, 379, 286	40	11
32	Quantification of absolute myocardial perfusion in patients with coronary artery disease: comparison between cardiovascular magnetic resonance and positron emission tomography. *Journal of the American College of Cardiology*, **2012**, 60, 1546-55	15.1	164
31	Cyberknife radiosurgery for focal paravertebral recurrence after radical pleurectomy/decortication in malignant pleural mesothelioma. *European Journal of Cardio-thoracic Surgery*, **2012**, 41, 1393-4	3	5
30	Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a Negative PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial. *Blood*, **2012**, 120, 547-547	2.2	29
29	The Role of Imaging in Radiotherapy for Hodgkin Lymphoma **2011**, 81-89		1

28	Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. *British Journal of Haematology*, **2011**, 152, 551-60	4.5	115
27	Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. *Annals of Oncology*, **2011**, 22, 739-745	10.3	53
26	Unilateral diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and multiple carcinoids treated with surgical resection. *Journal of Thoracic Oncology*, **2010**, 5, 921-3	8.9	13
25	Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma. *Journal of Thoracic Oncology*, **2010**, 5, 385-8	8.9	32
24	Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2010**, 37, 1824-33	8.8	235
23	Retrospective data-driven respiratory gating for PET/CT. *Physics in Medicine and Biology*, **2009**, 54, 1935-50	3.8	88
22	PET/CT for therapy response assessment in lymphoma. *Journal of Nuclear Medicine*, **2009**, 50 Suppl 1, 21S-30S	8.9	158
21	Intractable hiccups causing avid FDG uptake in the muscles of respiration. *European Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 36, 1901	8.8	
20	Opportunistic infection and nuclear medicine. *Seminars in Nuclear Medicine*, **2009**, 39, 88-102	5.4	6
19	Guidelines for the use of PET-CT in children. *Nuclear Medicine Communications*, **2008**, 29, 418-24	1.6	20
18	Measurement of the internal dose to families of outpatients treated with 131I for hyperthyroidism. *European Journal of Nuclear Medicine and Molecular Imaging*, **2008**, 35, 2097-104	8.8	16
17	Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a Negative FDG-PET Scan after 3 Cycles ABVD. *Blood*, **2008**, 112, 369-369	2.2	14
16	FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. *Lung Cancer*, **2007**, 55, 75-8	5.9	58
15	The new EANM paediatric dosage card--does it conform to ALARA for PET/CT?. *European Journal of Nuclear Medicine and Molecular Imaging*, **2007**, 34, 1881-2	8.8	7
14	18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. *Clinical Endocrinology*, **2006**, 64, 371-4	3.4	22
13	Comparison of sestamibi, thallium, echocardiography and PET for the detection of hibernating myocardium. *European Journal of Nuclear Medicine and Molecular Imaging*, **2004**, 31, 355-61	8.8	13
12	Limitations of PET for imaging lymphoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2003**, 30 Suppl 1, S117-27	8.8	96
11	Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. *British Journal of Haematology*, **2002**, 117, 133-5	4.5	48

10	Cost-effectiveness of preoperative positron emission tomography in ischemic heart disease. *Annals of Thoracic Surgery*, **2002**, 73, 1403-9; discussion 1410	2.7	18
9	Positron emission tomography in imaging spinal cord tumors. *Journal of Child Neurology*, **2000**, 15, 465-72	2.5	29
8	Interictal 18FDG PET findings in temporal lobe epilepsy with dj□vu. *Journal of Neuropsychiatry and Clinical Neurosciences*, **1999**, 11, 380-6	2.7	17
7	Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. *British Journal of Cancer*, **1999**, 79, 478-82	8.7	85
6	Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism. *European Journal of Nuclear Medicine and Molecular Imaging*, **1999**, 26, 686-92	8.8	59
5	Clinical value of "ictal" FDG-positron emission tomography and the routine use of simultaneous scalp EEG studies in patients with intractable partial epilepsies. *Epilepsia*, **1998**, 39, 753-66	6.4	44
4	Detection of Lymphoma in Bone Marrow by Whole-Body Positron Emission Tomography. *Blood*, **1998**, 91, 3340-3346	2.2	260
3	The effects of standardization and reference values on patient classification for spine and femur dual-energy X-ray absorptiometry. *Osteoporosis International*, **1997**, 7, 200-6	5.3	47
2	Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. *European Journal of Nuclear Medicine and Molecular Imaging*, **1996**, 23, 123-30		81
1	Bone mineral densitometry in clinical practice. Differences in reference values are important. *BMJ: British Medical Journal*, **1995**, 311, 1300-1		1